imeroprubart (IMVT-1402) — Topline data
H2 2026
The trial is fully enrolled and we expect to report top-line results from this trial in the second half of calendar year 2026.Source filing
IMVT biotech catalysts & pipeline
IMMUNOVANT INC · Data as of 2026-10-25
Upcoming catalysts
imeroprubart (IMVT-1402) — Topline data
2027
We expect to report top-line results from these trials in calendar year 2027.Source filing
imeroprubart (IMVT-1402) — Topline data
2027
We expect to report top-line results from this trial in calendar year 2027.Source filing
imeroprubart (IMVT-1402) — Topline data
2028
We expect to report top-line results from this trial in calendar year 2028.Source filing
imeroprubart (IMVT-1402) — Topline data
2028
We expect to report top-line results from this trial in calendar year 2028.Source filing
imeroprubart (IMVT-1402) — Conference presentation
H2 2026
Further updates on this program are expected in the second half of calendar year 2026.Source filing